-
Product Insights
NewLyme Disease – Drugs In Development, 2024
Empower your strategies with our Lyme Disease – Drugs In Development, 2024 report and make more profitable business decisions. Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches, and headache. Risk factors include age, gender, and geographic location. Treatment includes antibiotics. The Lyme Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Lyme Disease, complete with...
-
Product Insights
NewUrinary Incontinence – Drugs In Development, 2024
Empower your strategies with our Urinary Incontinence – Drugs In Development, 2024 report and make more profitable business decisions. Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes, and other skin disorders. Risk factors include age, gender, overweight, smoking, and kidney diseases. Treatment includes anticholinergics and topical estrogen. The Urinary Incontinence drugs in development...
-
Product Insights
NewChronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024
Empower your strategies with our Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a...
-
Product Insights
NewEwing Sarcoma – Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
NewMalignant Pleural Mesothelioma – Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Mesothelioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and...
-
Product Insights
NewIschemia Reperfusion Injury – Drugs In Development, 2024
Empower your strategies with our Ischemia Reperfusion Injury – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension,...
-
Product Insights
NewBurkitt Lymphoma – Drugs In Development, 2024
Empower your strategies with our Burkitt Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in...
-
Product Insights
NewPediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pediatric diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive type of brain tumor that primarily affects children, usually between the ages of five and 10 years. This tumor arises in the brainstem, specifically in the region known as the pons, which controls essential bodily functions such as breathing, heart rate, and muscle control. DIPG tumor location in...
-
Product Insights
NewMedulloblastoma – Drugs In Development, 2024
Empower your strategies with our Medulloblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to...
-
Product Insights
NewPontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, drooping of one side of the face, and difficulty...